Important Notice for ESSA Pharma Inc. (EPIX) Shareholders
NEW YORK, Feb. 10, 2025
The Gross Law Firm, a leading national shareholder rights law firm, issues this notice to investors in ESSA Pharma Inc. (EPIX) who purchased shares during the class period of August 1, 2023, and December 31, 2024. The firm is investigating potential securities fraud claims on behalf of shareholders.
Class Action Lawsuit Against ESSA Pharma Inc.
The investigation focuses on allegations that ESSA Pharma may have provided false and misleading information to the market regarding the development and regulatory status of its drug candidate, EPI-5895. According to the complaint, these false statements artificially inflated the price of ESSA Pharma’s stock.
What Does This Mean for EPIX Shareholders?
If you purchased shares of EPIX during the class period and suffered losses, you may be eligible to recover your investment. The lead plaintiff role in the class action is especially significant because the lead plaintiff works with the law firm to represent the interests of the class and negotiate a potential settlement.
How Will This Affect the World?
The potential consequences of this investigation extend beyond the EPIX shareholders. The pharmaceutical industry as a whole could face increased scrutiny and potential regulatory action if it is discovered that ESSA Pharma knowingly provided false information to the market.
What’s Next?
If you are an EPIX shareholder and wish to discuss your legal rights, please contact The Gross Law Firm at 888-227-1030 or via the firm’s website, [email protected]. You may also join the class action by visiting www.grosslawfirm.com/cases/epix.htm for more information.
Conclusion
The Gross Law Firm’s investigation into ESSA Pharma Inc. (EPIX) is a reminder that companies must provide accurate and truthful information to the investing public. Shareholders who purchased shares during the class period and suffered losses may be eligible to recover their investments. If you are an EPIX shareholder, contact The Gross Law Firm to discuss your legal rights.
- ESSA Pharma Inc. (EPIX) is under investigation for potential securities fraud.
- The investigation focuses on allegations of false and misleading statements regarding EPI-5895.
- Shareholders who purchased shares during the class period may be eligible to recover their investments.
- The consequences of this investigation could extend beyond EPIX shareholders.
- Contact The Gross Law Firm for more information.
